ARQT

Arcutis Biotherapeutics, Inc.

NasdaqHealthcarePharmaceutical Preparations

Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Latest filingAug 28, 2026Most recent Form 4
Total buying$00 buys
Total selling$115M5 sells
Net open-market-$115M3 insiders
Open-market mix
Buy vs sell distribution by transaction count
5 transactions
0 buys0%·100%5 sells

Insider activity report

Monthly open-market purchase and sale counts
Buys Sells
530-3-5transactionsAug 2026 sells: 5 transactions · $115M5AugSep

Transaction codes

By Form 4 transaction code in selected period
17transactions
  • M · Option exercise · dominant12 · 71%
  • S · Open-market sells5 · 29%

Activity by reported role

A joint filing can contribute to multiple roles
17transactions
  • Director · dominant16 · 94%
  • SR1 · 6%

Distinct insiders active

Reporting-owner CIKs by month · peak Aug 2026 (3)
Aug 2026Sep 2026
3distinct insiders in 2 months

Reported Holdings After

Separated by insider, security, and ownership type
Curran TerrieCommon Stock · Direct
50.6k23.5kAug 20, 2026 · 24,598 shares owned afterAug 20, 2026 · 23,526 shares owned afterAug 27, 2026 · 23,526 shares owned afterAug 27, 2026 · 50,578 shares owned afterAug 27, 2026 · 23,526 shares owned afterAug 27, 2026 · 34,674 shares owned afterAug 20, 2026Aug 27, 2026
34,674Aug 27, 2026
Welgus Howard G.Common Stock · Direct
41.2k36.5kAug 17, 2026 · 37,931 shares owned afterAug 17, 2026 · 38,950 shares owned afterAug 17, 2026 · 36,475 shares owned afterAug 17, 2026 · 41,205 shares owned afterAug 17, 2026Aug 17, 2026
41,205Aug 17, 2026
Welgus Howard G.Stock Option (right to buy) · Direct
20.3k7.4kAug 17, 2026 · 9,163 shares owned afterAug 17, 2026 · 7,396 shares owned afterAug 17, 2026 · 20,287 shares owned afterAug 17, 2026Aug 17, 2026
20,287Aug 17, 2026
Curran TerrieStock Option (right to buy) · Direct
11.1k0Aug 20, 2026 · 11,148 shares owned afterAug 27, 2026 · 0 shares owned afterAug 27, 2026 · 0 shares owned afterAug 20, 2026Aug 27, 2026
0Aug 27, 2026
Burnett PatrickCommon Stock · Direct
117.6k117.6kAug 19, 2026 · 117,592 shares owned afterAug 19, 2026Aug 19, 2026
117,592Aug 19, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells red
0 active days
Aug 04Sep 04
LessMore

Filing detail checks

Secondary metrics for the selected period
Largest buy-
Largest sale$67.7M
10b5-1 detected7
Amended rows0

ARQT transaction history

Filters apply within this company and selected period by default
Reset
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date

No transactions match your filters

Once the backend ingests and parses SEC filings, they will appear here. Try removing a filter or picking a wider date range.

Arcutis Biotherapeutics, Inc. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at Arcutis Biotherapeutics, Inc.?

Curran Terrie, Burnett Patrick, Welgus Howard G..

When was the latest reported open-market purchase?

No code-P purchase is available for this period.

When was the latest reported open-market sale?

Curran Terrie reported a sale on Aug 27, 2026 valued at $67.7M. Read the SEC filing.

What is the recent purchase and sale balance?

Net open-market selling in the selected period was $1,153,689.10. Sales can occur for many non-investment reasons.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.